Relieves mild to moderate acute pain. ANDA 210078, held by Onesource. Diclofenac Potassium.
As of Nov 16, 2026, ANDA 210078 (Diclofenac Potassium), held by Onesource, was first approved by FDA on Dec 3, 2019, with 5 approved supplements and 0 published complete response letters.
Diclofenac Potassium Capsules are indicated for relief of mild to moderate acute pain in adult and pediatric patients 12 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Potassium25MG · capsule;oral | Diclofenac Potassium | Rx |
| Jul 10, 2025 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 10, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 10, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jul 10, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 10, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 3, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters